Avid Bioservices Inc (CDMO): I think many here are overstating the im...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	32
Posts	1169
Boards Moderated	0
Alias Born	12/12/2005

mojojojo

Re: None

Wednesday, 05/29/2013 3:15:32 PM

Wednesday, May 29, 2013 3:15:32 PM

I think many here are overstating the importance of needing to get some really outstanding survival results from the 1st-line NSCLC trial. From a long term point of view, I don't think it's all that critical. Sure, any type of really good result would give additional evidence that bavi works but we already have great results from the 2nd-line trial. Even with outstanding survival results from the 1st-line trial, I doubt they'll run a phase 3 for that indication anytime soon. In the future, doctors aren't going to prescribe bavi for both 1st and 2nd-line treatment on the same patient. Since most all NSCLC patients end up taking 2nd-line treatment, being approved for 2nd-line treatment is good enough. Besides if a doctor really saw a need to prescribe it as a first-line treatment, he could do it off-label.

All IMO,

mojo